Douglass Winthrop Advisors LLC lowered its stake in Celgene Co. (NASDAQ:CELG) by 40.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,298 shares of the biopharmaceutical company’s stock after selling 2,900 shares during the period. Douglass Winthrop Advisors LLC’s holdings in Celgene were worth $405,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Bruderman Asset Management LLC acquired a new stake in Celgene in the fourth quarter valued at approximately $25,000. Murphy Pohlad Asset Management LLC acquired a new stake in Celgene in the fourth quarter valued at approximately $25,000. Athena Capital Advisors LLC acquired a new stake in Celgene in the fourth quarter valued at approximately $27,000. Liberty Wealth Management LLC acquired a new stake in Celgene in the fourth quarter valued at approximately $29,000. Finally, Berman Capital Advisors LLC acquired a new stake in Celgene in the fourth quarter valued at approximately $32,000. Hedge funds and other institutional investors own 74.92% of the company’s stock.

In related news, Director James J. Loughlin sold 23,466 shares of Celgene stock in a transaction on Thursday, February 7th. The shares were sold at an average price of $87.29, for a total transaction of $2,048,347.14. Following the completion of the transaction, the director now owns 62,102 shares of the company’s stock, valued at $5,420,883.58. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Ernest Mario bought 2,000 shares of the stock in a transaction that occurred on Tuesday, February 12th. The shares were purchased at an average cost of $89.99 per share, with a total value of $179,980.00. The disclosure for this purchase can be found here. 0.39% of the stock is owned by company insiders.

A number of brokerages have weighed in on CELG. Atlantic Securities lowered shares of Celgene from an “overweight” rating to a “neutral” rating and set a $94.34 target price on the stock. in a research report on Monday, April 1st. Sanford C. Bernstein downgraded shares of Celgene from an “outperform” rating to a “market perform” rating in a research note on Monday, April 1st. UBS Group downgraded shares of Celgene from a “buy” rating to a “neutral” rating and raised their price target for the company from $94.00 to $102.00 in a research note on Monday, April 1st. Jefferies Financial Group downgraded shares of Celgene from a “buy” rating to a “hold” rating and set a $95.00 price target for the company. in a research note on Friday, February 1st. Finally, Wells Fargo & Co dropped their price target on shares of Celgene from $90.00 to $84.00 and set a “market perform” rating for the company in a research note on Thursday, January 3rd. One analyst has rated the stock with a sell rating, eighteen have assigned a hold rating and nine have assigned a buy rating to the stock. Celgene has a consensus rating of “Hold” and an average target price of $99.41.

Shares of NASDAQ CELG opened at $94.09 on Wednesday. Celgene Co. has a twelve month low of $58.59 and a twelve month high of $95.30. The firm has a market cap of $66.58 billion, a P/E ratio of 12.36, a PEG ratio of 0.43 and a beta of 1.71. The company has a quick ratio of 2.12, a current ratio of 2.23 and a debt-to-equity ratio of 3.21.

Celgene (NASDAQ:CELG) last announced its earnings results on Thursday, January 31st. The biopharmaceutical company reported $2.39 earnings per share for the quarter, topping analysts’ consensus estimates of $2.32 by $0.07. Celgene had a net margin of 26.48% and a return on equity of 114.66%. The business had revenue of $4.04 billion during the quarter, compared to the consensus estimate of $3.98 billion. During the same quarter last year, the firm earned $2.00 earnings per share. On average, research analysts predict that Celgene Co. will post 10.01 EPS for the current fiscal year.

WARNING: “Celgene Co. (CELG) Shares Sold by Douglass Winthrop Advisors LLC” was first posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.watchlistnews.com/celgene-co-celg-shares-sold-by-douglass-winthrop-advisors-llc/2952660.html.

Celgene Company Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Recommended Story: Should You Consider an Index Fund?

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.